According to Zacks, “Bruker continues to witness strong year-over-year rise in organic revenues. We look forward to the company's Scientific Instruments segment that has been performing well driven by strong results from NANO and CALID groups. Bruker is progressing well with three strategic buyouts — majority interest in both Hain Diagnostics and Mestrelab along with Alicona Imaging acquisition. Further, it has made progress advancing proteomics and phenomics initiative with the rollout of timsTOF Pro and the gradual uptake of NMR phenomics. On the flip side, a competitive landscape and macroeconomic woes persistently pose challenges to the company. Growth within core BEST group was modest. Further, Bruker’s core BioSpin division faces fierce competition from companies offering magnetic resonance spectrometers. Through 2018, this business remained sluggish. Overall, Bruker underperformed the industry in the past six months.”
Several other brokerages have also commented on BRKR. BidaskClub upgraded shares of Bruker from a buy rating to a strong-buy rating in a research note on Friday, March 22nd. Needham & Company LLC initiated coverage on shares of Bruker in a research note on Wednesday, January 2nd. They set a strong-buy rating and a $39.00 price target on the stock. ValuEngine upgraded shares of Bruker from a hold rating to a buy rating in a research note on Tuesday, January 15th. BTIG Research reissued a buy rating and set a $44.00 price objective (up from $42.00) on shares of Bruker in a research report on Tuesday, February 12th. Finally, Deutsche Bank raised shares of Bruker from a hold rating to a buy rating and raised their price objective for the stock from $40.00 to $50.00 in a research report on Friday, April 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $38.14.
Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.54. Bruker had a net margin of 9.48% and a return on equity of 26.36%. The business had revenue of $553.60 million for the quarter, compared to analyst estimates of $544.53 million. Equities analysts expect that Bruker will post 1.57 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Shareholders of record on Tuesday, March 5th were paid a dividend of $0.04 per share. The ex-dividend date of this dividend was Monday, March 4th. This represents a $0.16 annualized dividend and a yield of 0.41%. Bruker’s dividend payout ratio is currently 11.43%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hanseatic Management Services Inc. boosted its stake in shares of Bruker by 52.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 579 shares during the period. Captrust Financial Advisors boosted its stake in shares of Bruker by 164.7% in the fourth quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 1,135 shares during the period. SG Americas Securities LLC acquired a new stake in Bruker in the fourth quarter valued at $176,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in Bruker in the fourth quarter valued at $192,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Bruker by 8.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,136 shares of the medical research company’s stock valued at $212,000 after acquiring an additional 550 shares in the last quarter. Institutional investors own 68.89% of the company’s stock.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Read More: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.